Lung Cancer最新文献

{"title":"Prediction recurrence in stage I epidermal growth factor receptor-mutated non-small cell lung cancer using multi-modal data","authors":"Akiko Tateishi ,&nbsp;Hidehito Horinouchi ,&nbsp;Nobuji Kouno ,&nbsp;Katsuji Takeda ,&nbsp;Ken Takasawa ,&nbsp;Takaaki Mizuno ,&nbsp;Yu Okubo ,&nbsp;Yukihiro Yoshida ,&nbsp;Mototaka Miyake ,&nbsp;Masahiko Kusumoto ,&nbsp;Koji Inaba ,&nbsp;Hiroshi Igaki ,&nbsp;Yasushi Yatabe ,&nbsp;Masami Mukai ,&nbsp;Naoki Mihara ,&nbsp;Jo Nishino ,&nbsp;Aya Kuchiba ,&nbsp;Taro Shibata ,&nbsp;Kouya Shiraishi ,&nbsp;Shun-ichi Watanabe ,&nbsp;Ryuji Hamamoto","doi":"10.1016/j.lungcan.2025.108727","DOIUrl":"10.1016/j.lungcan.2025.108727","url":null,"abstract":"<div><h3>Introduction</h3><div>Integrated recurrence prediction models that combine clinical, imaging, and genetic data are lacking for epidermal growth factor receptor (<em>EGFR)</em>-mutated stage I non-small cell lung cancer (NSCLC). We developed a recurrence prediction model for Stage I <em>EGFR</em>-mutated NSCLC by integrating clinical, radiological, and whole-exome sequencing (WES) data.</div></div><div><h3>Methods</h3><div>A total of 306 patients with Stage I <em>EGFR</em>-mutated NSCLC were stratified into training (n = 206) and validation (n = 100) cohorts using stratified random sampling. Cox proportional hazards models combined binary labels of clinical and radiological factors from univariate analysis, machine-learning-derived MultiGenes labels (determined by multiple gene mutations) from WES data, and high-impact gene mutations. Predictive performance was assessed using the concordance index (C-index), time-dependent area under the curve (AUC), and receiver operating characteristic curves. The top three models by category were evaluated using a survival analysis.</div></div><div><h3>Results</h3><div>Three optimal models were identified; the clinicoradiological model (Model 17) achieved a C-index of 0.70, the model incorporating clinicoradiological factors and MultiGenes (Model 28) achieved 0.69, and the clinicoradiological model with <em>TP53</em> mutations (Model 39) demonstrated the best performance, with 0.73. In Model 17, the 60-month recurrence-free survival (RFS) rates were 59.1 % for the high-risk group and 83.2 % for the low-risk group (hazard ratio [HR] = 3.47; 95 % confidence interval [CI]: 1.60–8.00). Model 39, which incorporated <em>TP53</em> mutations, demonstrated superior performance, with 60-month RFS rates of 57.1 % for the high-risk and 87.1 % for the low-risk groups (HR = 4.79; 95 %CI: 1.96–11.69).</div></div><div><h3>Conclusions</h3><div>Clinical and radiological factors are effective predictors of recurrence risk in Stage I <em>EGFR</em>-mutated NSCLC, and incorporating <em>TP53</em> mutation data further improves the prognostic accuracy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108727"},"PeriodicalIF":4.4,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating tumor macroenvironment, microenvironment and mechanobiology with organoid and organ-on-a-chip models for lung cancer immunotherapy","authors":"Yeonhee Park ,&nbsp;Da Hyun Kang ,&nbsp;Chaeuk Chung","doi":"10.1016/j.lungcan.2025.108726","DOIUrl":"10.1016/j.lungcan.2025.108726","url":null,"abstract":"<div><div>Lung cancer remains the leading cause of cancer-related mortality, and immune checkpoint inhibitors (ICIs) have revolutionized its treatment. However, immunotherapy responses vary significantly among patients, and adverse effects, such as immune-related pneumonitis, pose clinical challenges. Both the tumor macroenvironment (TMaE) and tumor microenvironment (TME) play pivotal roles in modulating immunotherapy outcomes; however, the complex crosstalk between them remains insufficiently characterized. This review discusses systemic (macroenvironmental) factors, including host metabolic status, coexisting pulmonary diseases, and baseline immune competence, alongside tumor-intrinsic (microenvironmental) determinants, such as programmed death-ligand 1 (PD-L1) expression, tumor mutation burden (TMB), and immune cell infiltration. Furthermore, we highlight the role of mechanotransduction pathways, including YAP/TAZ signaling, extracellular matrix (ECM) stiffness, and mechanical stress, in immune evasion, suggesting their potential as novel therapeutic targets. Finally, we explore emerging preclinical models simulating the TME and TMaE for immunotherapy response and safety assessment using lung cancer-derived organoids and organ-on-a-chip platforms. A deeper understanding of the interplay between TMaE and TME, combined with advanced modeling approaches, may ultimately lead to more precise and personalized immunotherapy strategies for patients with lung cancer.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108726"},"PeriodicalIF":4.4,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144902985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study","authors":"Alfonso Tafur ,&nbsp;Adeeb Sebai ,&nbsp;Zhuqing Shi ,&nbsp;Jun Wei ,&nbsp;Huy Tran ,&nbsp;S.Lilly Zheng ,&nbsp;Seth Krantz ,&nbsp;Thomas Hensing ,&nbsp;Aaron S. Mansfield ,&nbsp;Jianfeng Xu","doi":"10.1016/j.lungcan.2025.108712","DOIUrl":"10.1016/j.lungcan.2025.108712","url":null,"abstract":"<div><h3>Background</h3><div>Venous thromboembolism (VTE) is a major complication in lung cancer, and remains challenging to predict with current risk models. This study assesses the utility of a Polygenic Score (PGS) for VTE risk stratification in lung cancer patients.</div></div><div><h3>Methods</h3><div>Analyzing UK Biobank data with 3,241 lung cancer patients, we explored the association between a high PGS, with and without positive monogenic mutations (factor V Leiden [FVL]/ prothrombin gene mutation [PGM]), and VTE incidence. Two definitions of VTE incidence were used: “restricted location VTE” (pulmonary embolism or lower extremity thrombosis) and “any VTE” (inclusive of all venous thromboses).</div></div><div><h3>Results</h3><div>A high PGS was strongly associated with an increased VTE, including in subgroup analysis with adjustment for comorbidities. A previous VTE (Hazard ratio [HR]: 5.5) and metastasis (HR: 2.52) predicted increased risk of VTE. In addition, the top PGS quartile predicted VTE in both the any VTE definition: HR 1.35 (with FVL/PGM) and 1.39 (without FVL/PGM); and in the restricted location VTE: HR 1.38 (without FVL/PGM); all p ≤ 0.05. The 12-month VTE incidence confirmed the predictive discrimination of the PGS regardless of FVL/PGM status.</div></div><div><h3>Conclusion</h3><div>The PGS identified lung cancer patients at higher inherited risk for VTE, suggesting its potential for personalized prophylaxis and improved clinical outcomes.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108712"},"PeriodicalIF":4.4,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non–Small-Cell lung cancer”","authors":"M.M. Smeenk ,&nbsp;V. van der Noort ,&nbsp;C.J. de Gooijer ,&nbsp;W.S.M.E. Theelen","doi":"10.1016/j.lungcan.2025.108725","DOIUrl":"10.1016/j.lungcan.2025.108725","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108725"},"PeriodicalIF":4.4,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144902986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer","authors":"Takashi Kurosaki ,&nbsp;Hiroaki Kanemura ,&nbsp;Tomoyuki Otani ,&nbsp;Yusuke Kawanaka ,&nbsp;Yasushi Fukuda ,&nbsp;Keita Kudo ,&nbsp;Junko Tanizaki ,&nbsp;Shinichiro Suzuki ,&nbsp;Shuta Tomida ,&nbsp;Kazuko Sakai ,&nbsp;Yasutaka Chiba ,&nbsp;Akihiko Ito ,&nbsp;Kazuto Nishio ,&nbsp;Kazuhiko Nakagawa ,&nbsp;Hidetoshi Hayashi","doi":"10.1016/j.lungcan.2025.108723","DOIUrl":"10.1016/j.lungcan.2025.108723","url":null,"abstract":"<div><h3>Background</h3><div>B7-H3 and delta-like ligand 3 (DLL3) are novel therapeutic targets in extensive-stage small cell lung cancer (ES-SCLC). We aimed to assess the impact of B7-H3 and DLL3 expression on the tumor immune microenvironment (TME) and on the therapeutic efficacy of programmed cell death–ligand 1 (PD-L1) blockade for ES-SCLC.</div></div><div><h3>Patients and methods</h3><div>A total of 146 ES-SCLC patients who received platinum-based chemotherapy either with (Chemo + ICI cohort) or without (Chemo cohort) an immune checkpoint inhibitor was analyzed. Progression-free survival (PFS) and overall survival (OS) were evaluated in each cohort according to B7-H3 or DLL3 expression status as detected by immunohistochemistry. The relation of B7-H3 or DLL3 expression to characteristics of the TME was assessed by immune-related gene expression profiling (irGEP).</div></div><div><h3>Results</h3><div>In the Chemo + ICI cohort, patients with high B7-H3 expression showed a shorter PFS (median of 4.3 vs. 5.4 months; HR of 2.11 with a 95 % Cl of 1.08–4.10; <em>P</em> = 0.03) and OS (median of 8.4 vs. 14.2 months; HR of 1.83 with a 95 % CI of 0.91–3.69; <em>P</em> = 0.09) than those with low B7-H3 expression. In the Chemo cohort, there was no apparent difference in survival outcomes between the high and low B7-H3 expression groups. The irGEP analysis revealed that the effector function of CD8⁺ T cells was impaired in tumors with high B7-H3 expression. No clear association was apparent between therapeutic efficacy and DLL3 expression status.</div></div><div><h3>Conclusions</h3><div>High B7-H3 expression may serve as a resistance mechanism for PD-L1 antibody therapy by promoting T cell dysfunction in ES-SCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108723"},"PeriodicalIF":4.4,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy","authors":"Alberto Guijosa ,&nbsp;Eduardo Rios-Garcia ,&nbsp;David Dávila-Dupont ,&nbsp;Graciela Cruz-Rico ,&nbsp;Alessandro Russo ,&nbsp;Luis Antonio Cabrera Miranda ,&nbsp;Andres F Cardona ,&nbsp;Christian Rolfo ,&nbsp;Oscar Arrieta","doi":"10.1016/j.lungcan.2025.108722","DOIUrl":"10.1016/j.lungcan.2025.108722","url":null,"abstract":"<div><h3>Background</h3><div><em>EGFR</em>-TKIs have markedly enhanced outcomes for non-small cell lung cancer (NSCLC) patients, but resistance development is virtually inevitable. In the context of oligoprogressive disease (OPD), local treatments can target resistant clones while <em>EGFR</em>-TKIs maintain systemic control, potentially extending the duration of therapy. However, identifying patients who benefit from this combined approach remains unclear.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study on advanced <em>EGFR</em>-NSCLC patients with OPD during TKI therapy, treated with local therapy and continued TKI. Serum liquid biopsies for ctDNA <em>EGFR</em> mutations were performed at oligoprogression. We assessed the effect of liquid biopsy status and relevant clinical variables on progression-free survival-2 (PFS2; OPD to progression), overall survival-2 (OS2; OPD to death), overall survival-1 (OS1; diagnosis to death) and time to TKI discontinuation (TTD; TKI initiation to discontinuation).</div></div><div><h3>Results</h3><div>Among 84 patients, 70 had liquid biopsies, with 56 % testing positive for ctDNA. A positive liquid biopsy was associated with worse PFS2 (4.99 vs. 11.73 months, <em>p</em> &lt; 0.001), OS2, OS1 and TTD. In stratified analysis, CNS oligoprogression showed no PFS2 difference by liquid biopsy status, whereas non-CNS oligoprogression revealed a significant difference (5.13 vs. 13.70 months, <em>p</em> &lt; 0.001). Univariate analysis linked shorter PFS1, CNS progression, poor PS, high carcinoembryonic antigen, and non-SBRT radiotherapy to worse PFS2, while multivariate analysis identified liquid biopsy positivity as the only independent factor.</div></div><div><h3>Conclusions</h3><div>Liquid biopsy status is a significant prognostic marker in extracranial <em>EGFR</em>-oligoprogressive NSCLC, suggesting its potential in identifying patients who may benefit from continued TKI and local therapies. Further prospective studies are warranted to confirm these findings and explore alternative treatment strategies for OPD.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108722"},"PeriodicalIF":4.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144892802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)","authors":"P. Ciammella ,&nbsp;F. Iori ,&nbsp;P. Borghetti ,&nbsp;M. Galaverni ,&nbsp;E. Alì ,&nbsp;M. Tiseo ,&nbsp;M. Pagano ,&nbsp;M. Sepulcri ,&nbsp;V. Scotti ,&nbsp;N. GiajLevra ,&nbsp;M. Marcenaro ,&nbsp;N. Simoni ,&nbsp;V. Nardone ,&nbsp;A. Botti ,&nbsp;S. Cozzi ,&nbsp;A. Bruni","doi":"10.1016/j.lungcan.2025.108718","DOIUrl":"10.1016/j.lungcan.2025.108718","url":null,"abstract":"<div><h3>Background</h3><div>Despite the advances introduced by the PACIFIC trial, recurrence after definitive chemoradiotherapy (CRT) followed by durvalumab consolidation remains a significant clinical challenge in unresectable stage III non-small cell lung cancer (NSCLC). This study aims to investigate relapse patterns and outcomes of salvage treatments in a real-world cohort, providing insights for post-progression management.</div></div><div><h3>Methods</h3><div>We performed a retrospective analysis of 166 patients with unresectable stage III NSCLC treated with the PACIFIC regimen across eight Italian centers from January 2018 to December 2021. Recurrences were classified as oligorecurrent (≤3 lesions amenable to local therapy) or polyrecurrent. The impact of salvage strategies on overall survival (OS) was reported.</div></div><div><h3>Results</h3><div>After a median follow-up of 33 months, 56 % of patients experienced recurrence; among these, 72 % were oligorecurrent. Oligorecurrences predominantly involved the lungs (34 %) and brain (26 %), mostly outside the irradiated field. Median OS was significantly longer in oligorecurrent versus polyrecurrent patients (41 vs. 19 months). Salvage therapies in oligorecurrent patients included radiotherapy (RT) (45 %), chemotherapy (35 %), and CRT (13 %). Median OS was 25 months for those treated with RT alone and 30 months for those receiving CRT. Polyrecurrent patients primarily underwent chemotherapy (77 %) with a median OS of 12 months.</div></div><div><h3>Conclusions</h3><div>Oligorecurrence represented the predominant pattern of relapse post-CRT and durvalumab, associated with improved survival when treated with metastasis-directed therapies. These findings underscore the importance of stratifying recurrence patterns and integrating local salvage treatments, especially RT, in personalized management. Prospective trials are needed to refine salvage strategies and evaluate novel therapeutic combinations.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108718"},"PeriodicalIF":4.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-time non-invasive localization in sub-lobar resection for small pulmonary nodules: a noninferiority randomized clinical trial","authors":"Yu Jiang ,&nbsp;Yuechun Lin ,&nbsp;Lili Mo ,&nbsp;Hongsheng Deng,&nbsp;Runchen Wang,&nbsp;Jianqi Zheng,&nbsp;Jun Liu,&nbsp;Wei Wang,&nbsp;Zhexue Hao,&nbsp;Huanghe He,&nbsp;Ying Huang,&nbsp;Wenhua Liang,&nbsp;Fei Cui,&nbsp;Jianxing He,&nbsp;Hengrui Liang","doi":"10.1016/j.lungcan.2025.108724","DOIUrl":"10.1016/j.lungcan.2025.108724","url":null,"abstract":"<div><h3>Background</h3><div>Sub-lobar resection is a well-established surgical approach for solitary pulmonary ground-glass opacity (GGO) lesions. However, conventional CT-guided percutaneous localization is associated with complications such as pneumothorax, hemothorax, and patient discomfort. To address these concerns, a novel real-time, non-invasive localization technique was developed. This study aimed to evaluate the effectiveness and safety of this innovative method for localizing small pulmonary nodules during sub-lobar resection.</div></div><div><h3>Methods</h3><div>A non-inferiority randomized clinical trial was conducted at the First Affiliated Hospital of Guangzhou Medical University from July 2022 to July 2023. Patients were randomized 1:1 to either non-invasive or CT-guided localization. The primary endpoint was the successful resection rate. Secondary endpoints included margin distance, surgical plan changes, conversion rate, intraoperative blood loss, chest tube placement duration, postoperative hospital stay, localization-related and postoperative complications, and 30-day postoperative mortality.</div></div><div><h3>Results</h3><div>Of the 440 randomized patients, 430 underwent surgery. The successful resection rate was comparable between the non-invasive and CT-guided groups (98.1 % vs. 98.6 %; P = 0.703). No significant differences were observed in margin distance, intraoperative blood loss, chest tube duration, postoperative hospital stay, or postoperative complication rates. Localization-related complications were significantly higher in the CT-guided group, including misplacement (9.8 %), puncture site pain (55.8 %), pneumothorax (42.3 %), and minor hemorrhage (30.2 %). No localization-related complications occurred in the non-invasive group.</div></div><div><h3>Conclusions</h3><div>The novel non-invasive localization technique demonstrated comparable effectiveness to CT-guided localization for sub-lobar resection, with significantly fewer localization-related complications, offering a safer alternative for managing small pulmonary nodules.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108724"},"PeriodicalIF":4.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non–small cell lung cancer","authors":"Hai-Yan Tu ,&nbsp;Chun Chen ,&nbsp;Chang Chen ,&nbsp;Chao Cheng ,&nbsp;Ying Cheng ,&nbsp;Junke Fu ,&nbsp;Feng Jiang ,&nbsp;Gaofeng Li ,&nbsp;Yongde Liao ,&nbsp;Jiwei Liu ,&nbsp;Shun Lu ,&nbsp;Wei-Min Mao ,&nbsp;Pingping Song ,&nbsp;Yong Song ,&nbsp;Qun Wang ,&nbsp;Fan Yang ,&nbsp;Yi Yang ,&nbsp;Jianming Ying ,&nbsp;Jun Zhao ,&nbsp;Wen-Zhao Zhong ,&nbsp;Yi-Long Wu","doi":"10.1016/j.lungcan.2025.108716","DOIUrl":"10.1016/j.lungcan.2025.108716","url":null,"abstract":"<div><div>This Chinese expert consensus addresses comprehensive recommendations on biomarker testing, treatment, and follow-up in the perioperative management of patients with resectable ALK-fusion non-small cell lung cancer (NSCLC). The document highlights the pivotal role of cancer genomic testing in informing personalized therapeutic decision-making. The application of perioperative targeted therapies, including alectinib, has demonstrated significant potential in improving clinical outcomes for patients with ALK-fusion NSCLC. The consensus further underscores the necessity for expanded clinical research and trials to optimize and validate individualized treatment strategies, thereby advancing the standard of care in this patient population.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"208 ","pages":"Article 108716"},"PeriodicalIF":4.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in use of radiotherapy for lung cancer – A Norwegian population-based study from 2000 until 2020","authors":"Gustav Graabak ,&nbsp;Tarje Onsøien Halvorsen ,&nbsp;Bjørn Henning Grønberg ,&nbsp;Kristin Toftaker Killingberg","doi":"10.1016/j.lungcan.2025.108720","DOIUrl":"10.1016/j.lungcan.2025.108720","url":null,"abstract":"<div><h3>Background</h3><div>Radiotherapy (RT) is an important treatment modality for cancer. It requires significant resources, building facilities takes time, and planning of the capacity is essential to offer RT to all patients in need. There have been considerable advances in lung cancer management, especially medical treatment, and survival the last decades, which might impact the need for RT. In this study, we investigated whether the RT use for lung cancer has changed in Norway since year 2000.</div></div><div><h3>Methods</h3><div>Data on patients diagnosed with lung cancer between 2000 and 2020 were collected from the Cancer Registry of Norway, containing nearly complete RT and survival data.</div></div><div><h3>Results</h3><div>55,048 patients were analyzed. Median age was 71 years, 44 % were women, 74 % had non-small-cell lung cancer, 16 % small-cell lung cancer, 10 % unknown histology, 46 % metastatic disease. Overall, 50 % received any RT. The proportion receiving curative RT increased (2000: 10 %, 2020: 22 %), mainly due to implementation of stereotactic body RT (&lt;1% before 2008, 11 % in 2020). The proportion receiving palliative RT increased the first decade (2000: 30 %, 2010: 42 %) before decreasing to 30 % in 2020, mainly due to less use of palliative thoracic and whole-brain RT. Number of RT courses per year increased (from 1283 to 2328), courses per patient decreased the last decade (from 0.82 to 0.76). Median overall survival improved significantly (2000–2004: 6.2 months, 2016–2020: 14.0 months, p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>There was a shift towards more curative and less palliative RT from 2000 until 2020. Overall, the use of RT for lung cancer increased during this period.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108720"},"PeriodicalIF":4.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144889862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}